WGS PE Ratio & Valuation,Is WGS Overvalued

WGS Relative Valuation

WGS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, WGS is overvalued; if below, it's undervalued.

Historical Valuation

GeneDx Holdings Corp (WGS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 8.67 is considered Overvalued compared with the five-year average of 26.39. The fair price of GeneDx Holdings Corp (WGS) is between 99.11 to 132.57 according to relative valuation methord. Compared to the current price of 151.51 USD , GeneDx Holdings Corp is Overvalued By 14.28%.

Relative Value

Fair Zone

99.11-132.57

Current Price：151.51

14.28%

Overvalued

501.06

2551.42

EV/EBITDA

GeneDx Holdings Corp. (WGS) has a current EV/EBITDA of 2551.42. The 5-year average EV/EBITDA is -36.53. The thresholds are as follows: Strongly Undervalued below -1157.93, Undervalued between -1157.93 and -597.23, Fairly Valued between 524.17 and -597.23, Overvalued between 524.17 and 1084.88, and Strongly Overvalued above 1084.88. The current Forward EV/EBITDA of 2551.42 falls within the Strongly Overvalued range.

443.19

EV/EBIT

GeneDx Holdings Corp. (WGS) has a current EV/EBIT of 443.19. The 5-year average EV/EBIT is 11.94. The thresholds are as follows: Strongly Undervalued below -180.30, Undervalued between -180.30 and -84.18, Fairly Valued between 108.06 and -84.18, Overvalued between 108.06 and 204.18, and Strongly Overvalued above 204.18. The current Forward EV/EBIT of 443.19 falls within the Strongly Overvalued range.

8.67

GeneDx Holdings Corp. (WGS) has a current PS of 8.67. The 5-year average PS is 17.29. The thresholds are as follows: Strongly Undervalued below -61.88, Undervalued between -61.88 and -22.29, Fairly Valued between 56.87 and -22.29, Overvalued between 56.87 and 96.46, and Strongly Overvalued above 96.46. The current Forward PS of 8.67 falls within the Historic Trend Line -Fairly Valued range.

467.54

P/OCF

GeneDx Holdings Corp. (WGS) has a current P/OCF of 467.54. The 5-year average P/OCF is -1014.89. The thresholds are as follows: Strongly Undervalued below -11332.54, Undervalued between -11332.54 and -6173.71, Fairly Valued between 4143.94 and -6173.71, Overvalued between 4143.94 and 9302.77, and Strongly Overvalued above 9302.77. The current Forward P/OCF of 467.54 falls within the Historic Trend Line -Fairly Valued range.

107.87

P/FCF

GeneDx Holdings Corp. (WGS) has a current P/FCF of 107.87. The 5-year average P/FCF is 13.07. The thresholds are as follows: Strongly Undervalued below -56.29, Undervalued between -56.29 and -21.61, Fairly Valued between 47.75 and -21.61, Overvalued between 47.75 and 82.43, and Strongly Overvalued above 82.43. The current Forward P/FCF of 107.87 falls within the Strongly Overvalued range.

GeneDx Holdings Corp (WGS) has a current Price-to-Book (P/B) ratio of 14.96. Compared to its 3-year average P/B ratio of 5.08 , the current P/B ratio is approximately 194.50% higher. Relative to its 5-year average P/B ratio of 3.49, the current P/B ratio is about 329.23% higher. GeneDx Holdings Corp (WGS) has a Forward Free Cash Flow (FCF) yield of approximately 0.35%. Compared to its 3-year average FCF yield of -97.40%, the current FCF yield is approximately -100.36% lower. Relative to its 5-year average FCF yield of -70.82% , the current FCF yield is about -100.50% lower.

14.96

P/B

Median3y

5.08

Median5y

3.49

0.35

FCF Yield

Median3y

-97.40

Median5y

-70.82

Competitors Valuation Multiple

The average P/S ratio for WGS's competitors is 4.60, providing a benchmark for relative valuation. GeneDx Holdings Corp Corp (WGS) exhibits a P/S ratio of 8.67, which is 88.32% above the industry average. Given its robust revenue growth of 51.86%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of WGS increased by 97.12% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 1.11K to 2.06K.

The secondary factor is the Revenue Growth, contributed 51.86%to the performance.

Overall, the performance of WGS in the past 1 year is driven by P/E Change. Which is more unsustainable.

51.86%

76.87M → 116.74M

Revenue Growth

-39.50%

-10.81 → -6.54

Margin Expansion

84.76%

1.11K → 2.06K

P/E Change

97.12%

76.86 → 151.51

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is GeneDx Holdings Corp (WGS) currently overvalued or undervalued?

What is GeneDx Holdings Corp (WGS) fair value?

WGS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of GeneDx Holdings Corp (WGS) is between 99.11 to 132.57 according to relative valuation methord.

How does WGS's valuation metrics compare to the industry average?

What is the current P/B ratio for GeneDx Holdings Corp (WGS) as of Dec 15 2025?

As of Dec 15 2025, GeneDx Holdings Corp (WGS) has a P/B ratio of 14.96. This indicates that the market values WGS at 14.96 times its book value.

What is the current FCF Yield for GeneDx Holdings Corp (WGS) as of Dec 15 2025?

As of Dec 15 2025, GeneDx Holdings Corp (WGS) has a FCF Yield of 0.35%. This means that for every dollar of GeneDx Holdings Corp’s market capitalization, the company generates 0.35 cents in free cash flow.

What is the current Forward P/E ratio for GeneDx Holdings Corp (WGS) as of Dec 15 2025?

As of Dec 15 2025, GeneDx Holdings Corp (WGS) has a Forward P/E ratio of 501.06. This means the market is willing to pay $501.06 for every dollar of GeneDx Holdings Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for GeneDx Holdings Corp (WGS) as of Dec 15 2025?

As of Dec 15 2025, GeneDx Holdings Corp (WGS) has a Forward P/S ratio of 8.67. This means the market is valuing WGS at $8.67 for every dollar of expected revenue over the next 12 months.

WGS Valuation